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California, San Francisco, California
Because calcium oxalate renal stones are the most
common type of renal calculus found in this country,
a discussion of oxalic acid and abnormalities associ-
ated with its synthesis and excretion seems war-
ranted in a symposium of this sort. Although calcium
metabolism and excretion have been investigated
extensively in syndromes associated with recurrent
nephrolithiasis, relatively little attention has been
paid to oxalate in these conditions. Nevertheless,
information now available, particularly concerning
the known hyperoxaluric conditions, has led to
greater understanding of idiopathic calcium oxalate
nephrolithiasis and more rational treatment of this
condition. In this review, the physicochemical and
metabolic aspects of oxalic acid will be reviewed,
followed by a discussion of the hyperoxaluric syn-
dromes and the role of oxalate in idiopathic calcium
oxalate stone disease.
Oxalic acid
Physicochemical aspects. Oxalic acid is the sim-
plest dicarboxylic acid found in nature. It is a major
constituent of a number of green leafy vegetables and
plants and has been used extensively in industry as a
bleaching and cleaning agent. It is a strong organic
acid with a pKa of 1.2. It forms acid and neutral
salts, mono- and diesters, and mono- and diamides.
Its major clinical significance in man relates to the
extreme insolubility of the calcium salt of oxalate. At
neutral pH, the calcium salt is soluble in water only
to the extent of 0.67 mg'lOO g of water. This solubil-
ity is little affected by changes in pH within the
physiologic range found in urine (4.5 to 7.5) [1].
Because of this limited solubility, it is not surprising
that normal human urine is often supersaturated with
respect to calcium oxalate [2, 3]. As discussed in Dr.
Fleisch's article (this issue), crystallization is proba-
bly prevented by a number of inhibitors, including
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urea, organic acids, polypeptides, mucopolysacchar-
ides, pyrophosphate, trace metals, and certain col-
bids [4].
Dietary sources and absorption. Oxalic acid is
found in a variety of foodstuffs including pepper,
parsley, spinach, rhubarb, cocoa, tea, and certain
other dark green leafy vegetables and plants. Estima-
tion of the amount of oxalate in the diet is difficult
because of the problem of complete extraction of
oxalate from foods in the experimental assays. This
is emphasized in a very practical way when the
oxalate content of tea is examined. If tea is allowed
to steep only a short period of time, only a few
milligrams of oxalate/1,000 ml are found. If tea is
allowed to steep several minutes to obtain a dark
amber-looking solution, however, as much as 68 mgI
1,000 ml may be found [5]. Reports in the past have
indicated a wide variation of oxalate intake, between
100 and 1,000 mg124 hr [6, 7]. No new data are
available to determine accurately the oxalate content
of the average American diet.
The absorption of oxalate by the gastrointestinal
tract has received a great deal of attention in recent
years in view of the association of hyperoxaluria and
certain gastrointestinal diseases [8]. In normal man,
oxalate is poorly absorbed by the gastrointestinal
tract, probably because a major proportion of that
ingested exists as relatively insoluble calcium oxalate
within the lumen of the tract. In previous studies
using stable oxalate, absorption in the fasting state
was estimated at 2.3 to 4.5% of the administered load
(800 to 1200 mg) [9]. More recently, studies of oxa-
late absorption using the '4C-radioisotope have indi-
cated that 12% of the administered tracer load is
absorbed in the fasting state [10]. This absorption
takes place throughout the entire gastrointestinal
tract including the colon, and animal studies have
shown this to be a passive nonenergy-requiring diffu-
sion process [11].
Excretion and renal clearance. Oxalate absorbed
from the gastrointestinal tract together with that pro-
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duced from endogeneous metabolic sources (see sub-
sequent section on biosynthesis) is excreted un-
changed in the urine because no significant
metabolism of oxalate occurs in man. Oxalate con-
tent of urine in normal persons generally varies be-
tween 10 and 50 mg/24 hr, using the isotope dilution
method [12]. Some argument exists as to the upper
limit of the normal range, because some studies of
oxalate excretion in normal subjects using different
assay procedures report 40 mg124 hr as the upper
limit [21.
The renal clearance of oxalate has been studied by
isotopic methods in man [13, 141. Filtration of oxa-
late at the glomerulus appears to be complete in view
of the absence of significant protein binding of oxa-
late in plasma. An oxalate:creatinine clearance ratio
of >1 has suggested that active secretion of oxalate
takes place somewhere in the renal tubule [13]. No
micropuncture studies of renal oxalate handling have
been reported, probably because of the great diffi-
culty in measuring small quantities of oxalate. No
defect in the renal handling of oxalate has been
proved in the several hyperoxaluric states.
Biosynthesis of oxalate. Because oxalate absorp-
tion from the gastrointestinal tract is normally quite
small, most urinary oxalate is derived from endog-
enous sources [15]. Oxalate, like uric acid, is a use-
less end product of metabolism, there being no sig-
nificant metabolism of oxalate in mammalian
species. The two major sources of oxalate are ascor-
bic acid and glyoxylic acid. The exact steps in the
oxidation of ascorbate to oxalate are not well under-
stood, but the first two carbons of the ascorbate
molecule are converted to oxalate and account for
about 30% of the oxalate eventually excreted by
normal subjects [161. No abnormalities in this meta-
bolic pathway have been identified in man.
The most important precursor of oxalate is glyox-
ylate, an extremely reactive compound that under-
goes a number of metabolic reactions (Fig. 1). Glyox-
ylate is oxidized to oxalate in the cytosol by lactic
dehydrogenase and nicotinamide adenine dinucleo-
tide [171. Glycolic acid oxidase and xanthine oxidase
are both capable of catalyzing the conversion of
glyoxylate to oxalate, but data suggest that these
reactions are quantitatively unimportant in vivo [18].
The interconversion of glyoxylate and hydroxypro-
line is similarly of little quantitative importance, and
hydroxyproline does not appear to be an important
precursor of glyoxylate or oxalate [15]. Glyoxylate
can be synergistically decarboxylated in the pres-
ence of 2 oxo-glutarate and thiamine pyrophosphate
to ct-hydroxy-/3-ketoadipate, a reaction occurring in
both the cytosol and mitochondria [19]. The further
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Fig. 1. Pathways of oxa late biosynthesis. Abbreviations used are:
LDH, lactic dehydrogenase; GAO, glycolic acid oxidase; XO,
xanthine oxidase; PP, pyridoxal phosphate; aKG, 2 oxo-glutamte;
TPP, thiamine pyrophosphate.
fate of this compound is unclear. Glyoxylate is re-
duced to glycolate by glyoxylate reductase, and the
latter compound is oxidized to glyoxylate by glycolic
acid oxidase. Glyoxylate is transaminated to glycine
in the presence of pyridoxal phosphate, a reaction
accounting for the disposal of a major portion of the
glyoxylate pool [15]. D-amino acid oxidase can con-
vert glycine to glyoxylate, but this pathway does not
appear to be of major importance. Serine can be
converted to oxalate either through its conversion to
glycine or through the pathway of glycolate forma-
tion involving ethanolamine and glycoaldehyde as
intermediates [20]. Recent evidence in animal stud-
ies suggests that hydroxypyruvate may be a precur-
sor of oxalate, perhaps through its metabolism to
serine and glycolate [21]. Finally, glyoxylate may be
nonenzymatically decarboxylated by certain sulfhy-
dry! compounds [22]. Two extensive reviews of gly-
oxylate metabolism have been published recently
[15, 201.
Causes of hyperoxaluria
The major causes of hyperoxaluria are outlined in
Table 1. This classification is based on two major
pathogenetic mechanisms: increased endogenous
production of oxalate primarily from its major pre-
cursor glyoxylate and increased oxalate excretion
Table 1. Causes of hyperoxaluria
I. Increased endogenous production of oxalate
A. Increased intake of an oxalate precursor
1. Ethylene glycol
2. Methoxyfiurane
3. Xylitol
4. Ascorbic acid
B. Pyridoxine deficiency
C. Primary hyperoxaluria, types I and II
II. Increased oxalate intake or absorption
A. Excessive oxalate ingestion
B. Enteric hyperoxaluria
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secondary to increased intake or gastrointestinal ab-
sorption of oxalate.
Increased endogenous production of oxalate.
Three mechanisms have been invoked to explain
increased endogenous production of oxalate leading
to hyperoxaluria: 1) increased production of oxalate
secondary to the intake of a metabolic precursor of
oxalate, 2) pyridoxine deficiency, and 3) the primary
hyperoxalurias in which a genetic defect in the path-
ways of oxalate synthesis leads to increased oxalate
production. When ingested, ethylene glycol, a com-
mon ingredient of antifreeze solutions, is rapidly
converted to glyoxylate and oxalate, presumably
through the ethanolamine-glycoaldehyde-glycolate
pathway (see section on biosynthesis of oxalate).
Massive hyperoxaluria and intrarenal obstructive
uropathy have occurred after self-administration of
ethylene glycol [23]. The fluorinated, 2-carbon, anes-
thetic agent methoxyflurane can also be converted to
oxalate in the liver, and cases of acute renal failure
secondary to hyperoxaluria and intrarenal oxalate
deposition have been reported following the use of
this agent [241. Oxalosis in the absence of hyperoxal-
uria has been observed in several patients given large
doses of xylitol intravenously [251. It has been theo-
rized that the xylitol is metabolized to glycoaldehyde
and then to glycolate; however, the studies of Haus-
childt and Watts [26] do not support the concept that
xylitol is a precursor of urinary oxalate. Ascorbic
acid in very larges doses (>5 glday) has been re-
ported to increase urinary excretion of oxalate [27],
but marked hyperoxaluria after ascorbate ingestion
has not been observed.
Pyridoxine deficiency in experimental animals
leads to hyperoxaluria presumably by reduced trails-
amination of glyoxylate to glycine [28]. Similarly,
pyridoxine deficiency in man also leads to hyperoxal-
uria. Surprisingly, recent studies have not shown a
greater conversion of '4C-glyoxylate into urinary ox-
alate in pyridoxine-deficient animals [29]. Clinical
examples of hyperoxaluria secondary to pyridoxine
deficiency are extremely rare. Primary hyperoxaluria
types I and II will be discussed subsequently.
Increased intake or absorption of oxalate. Oxalosis
may be produced experimentally by the oral or par-
enteral administration of oxalate to laboratory ani-
mals, and very rare cases of oxalate poisoning have
been described in man. The most common hyper-
oxaluric syndrome in man is that associated with
chronic gastrointestinal disorders in which increased
absorption of ingested oxalate accounts for the
marked hyperoxaluria. This syndrome, termed en-
teric hyperoxaluria, will be described in detail later.
Primary hyperoxaluria
Primary hyperoxaluria types I and II are two ge-
netically distinct inborn errors of metabolism involv-
ing the biosynthetic pathways of oxalate. Both types
are associated with marked hyperoxaluria; oxalate
deposits are found in renal and extrarenal tissues in
the type I syndrome [15]. The clinical picture of the
more common type I syndrome is the appearance of
recurrent calcium oxalate renal calculi, usually be-
fore the age of six. If untreated, recurrent stone
formation leads to recurrent urinary tract infections
and chronic pyelonephritis. In addition, oxalate de-
posits eventually develop in a variety of extrarenal
tissues including bone marrow, heart, small blood
vessels, eye, and the central nervous system. Severe
chronic renal failure develops as a result of severe
interstitial nephritis secondary to oxalate deposits
and chronic pyelonephritis, and death may occur
before 20 years of age. Conduction disturbances in
the heart and localized ischemic lesions in the skin
and peripheral nerves may develop in some patients
[30]. Only four cases of the type II syndrome have
been described, and no definite evidence of tissue
oxalosis in this group of patients has yet been re-
ported. Variations in the phenotypic expression of
primary hyperoxaluria have been described [15]. In a
small number of patients with the presumed type I
syndrome, stone disease did not develop until after
the age of 20 years, and the clinical course was
generally milder. It is not yet known if these cases
represent genotypically true cases of primary
hyperoxaluria.
Both syndromes are inherited by the autosomal
recessive mode; and in both, the heterozygote car-
riers are free of stone disease and hyperoxaluria.
Diagnosis is based on the finding of persistent hyper-
oxaluria, usually > 100 mg124 hr, in the absence of
other causes of hyperoxaluria. In the type I syn-
drome, urinary excretion of both glyoxylate and gly-
colate is also increased. In the type II syndrome,
urinary excretion of glyoxylate and glycolate is
within normal limits or low, and large amounts of L-
glyceric acid are also found in the urine [311. Confir-
mation of the genetic syndromes is based on this
differing pattern of urinary organic acid excretion
and on the demonstration of a specific enzymatic
defect in each type.
The enzymatic defect and mechanism for the char-
acteristic organic aciduria has now been well docu-
mented for the type I syndrome. Absence of the
soluble thiamine pyrophosphate-dependent carboli-
gase enzyme, which converts glyoxylate to a-hy-
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droxy-13-ketoadipate, has been demonstrated in tis-
sues of patients with the type I syndrome [19]. The
mitochondrial isoenzyme is normal. Absence of this
catalytic activity in the cytosol leads to accumulation
of glyoxylate with increased synthesis and excretion
of both glycolate and oxalate. The resultant hyperox-
aluria then leads to excessive saturation of urine with
respect to calcium oxalate, and recurrent nephroli-
thiasis results. Tissue oxalate deposition eventually
occurs, particularly after renal failure ensues; the
specific tissue localization of calcium oxalate depos-
its is thought to be governed by local concentrations
of calcium ion [201.
The enzymatic defect in the type II syndrome lies
in the gluconeogenic pathway of serine metabolism
[151. Leukocytes of patients with the type II syn-
drome have been shown to lack catalytic activity of
D-glycenc dehydrogenase, an enzyme which cata-
lyzes the reduction of hydroxypyruvate to D-glycer-
ate [31]. In the absence of this enzymatic activity,
hydroxypyruvate accumulates and is reduced to L-
glycerate in the presence of lactic dehydrogenase
and nicotinamide adenine dinucleotide dehydroge-
nase (NADH).
The mechanism of the increased synthesis and
excretion of oxalate in the type II syndrome is not
immediately clarified by this enzymatic defect. Sev-
eral possible explanations exist. Evidence in plants
and microorganisms suggests a similarity between
the two enzymes D-glyceflc dehydrogenase and gly-
oxylate reductase [321. If these enzymes are indeed
the same, a parallel block could exist in both hy-
droxypyruvate metabolism to D-glycerate and in gly-
oxylate conversion to glycolate. Animal studies with
hydroxypyruvate-3-14C have suggested a precursor-
product relationship between hydroxypyruvate and
oxalate [21]. If such an interconversion exists in
man, hydroxypyruvate accumulation may lead di-
rectly to increased oxalate synthesis and excretion.
Finally, studies from this laboratory have suggested
a third explanation [33]. In studies of human erythro-
cytes and leukocytes and preparations of partially
purified lactic dehydrogenase, hydroxypyruvate en-
hanced oxalate synthesis and diminished glycolate
synthesis from glyoxylate, presumably through re-
duction of lactic dehydrogenase-NADH. These find-
ings suggest that increased oxalate synthesis in the
presence of D-glycerlc dehydrogenase deficiency is
the indirect result of coupled oxidation-reduction of
glyoxylate and hydroxypyruvate through their com-
mon nonspecific reactivity with lactic dehydroge-
nase. This explanation explains completely the par-
ticular organic acid pattern in the type II syndrome,
namely increased L-glyceric aciduria, hyperoxaluria,
and diminished excretion of both glycolate and gly-
oxylate. Further studies in patients with type II pri-
mary hyperoxaluria will be needed to test these three
hypotheses more accurately.
Enteric hyperoxaluria
Recently, a new hyperoxaluric syndrome has been
recognized in patients with a variety of malabsorp-
tive states in which gastrointestinal absorption of
oxalate is increased [8, 34—36]. The syndrome was
originally observed in patients with ileal resection
>50 cm. Recurrent calcium oxalate nephrolithiasis
secondary to marked hyperoxaluria developed in
these patients soon after surgery. The syndrome was
subsequently recognized in patients with significant
fat malabsorption secondary to a variety of other
chronic gastrointestinal disorders; i.e., chronic in-
flammatory bowel disease, chronic pancreatic and
biliary tract diseases, bacterial overgrowth syn-
drome, blind loop syndrome, and after jejunoileal
bypass procedures. Hyperoxaluria in these patients
usually varies between 100 and 300 mg124 hr. Uri-
nary glycolate and glycerate concentrations are
within normal limits. Pyridoxine deficiency has not
been identified in any of the patients studied.
Hyperabsorption of dietary oxalate has been dem-
onstrated repeatedly in these groups of patients [37,
38]. In our own studies, more than 40% of an orally
administered dose of isotopic oxalate was absorbed
by these patients, compared with a mean of 12% in
normal subjects [10]. The degree of hyperabsorption
of oxalate and the amount of oxalate excreted in the
urine appear to be directly related to the degree of fat
malabsorption [10]. Control of fat malabsorption by
dietary administration of mediuni-chain triglycer-
ides, reduction of dietary oxalate, and administration
of oral calcium supplements reduces oxalate excre-
tion toward normal levels in these patients [39].
Therefore, oxalate hyperabsorption and hyperoxalu-
na in these patients may result from the competition
of oxalate and fatty acids in the lumen of the small
intestine for intraluminal calcium ion. In the pres-
ence of normal fat absorption and adequate intralum-
inal calcium concentration, most oxalate in the intes-
tine exists as the insoluble and relatively
nonabsorbable calcium salt, which accounts for the
small amount of oral oxalate absorbed in normal
subjects. In the presence of significant fat malabsorp-
tion, the intraluminal fatty acid concentration in-
creases dramatically, binding calcium to form cal-
cium-fatty acid soaps and lowering the concentration
of intraluminal calcium ion. Therefore, more oxalate
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remains in solution and, as such, can diffuse freely
across the gastrointestinal wall, enabling hyperab-
sorption of oxalate.
This hypothesis has been supported by a number
of in vivo and in vitro studies [10, 391. Urinary
oxalate excretion will decrease in patients with this
syndrome 1) when they are placed on a low fat or
medium-chain triglyceride diet to reduce fatty acid
malabsorption, 2) when they are placed on a low or
zero oxalate intake, and 3) when they are given
modest oral calcium supplements. These in vivo
studies indicate the importance of relative intralumi-
nal concentrations of calcium and oxalate ions in the
gastrointestinal tract. In in vitro studies, calcium
oxalate solubility in aqueous solutions can be af-
fected significantly by alterations in the fatty acid
concentration of the solution. In aqueous solutions
containing calcium and oxalate, increasing sodium
oleate concentration to within the range expected to
occur in the lumen of the intestinal tract in patients
with malabsorption will lead to increased oxalate
solubility [401.
Other theories to explain the increased oxalate
absorption in these patients have also been offered.
Because these patients also have malabsorption of
bile acids, it has been proposed that unabsorbed bile
acids in some way may affect the diffusion of oxalate
across the luminal cell. This seems unlikely in view
of the passive diffusion process that exists for oxa-
late absorption [11], and in addition, it has not been
possible to increase oxalate absorption in patients
with enteric hyperoxaluria by the administration of
large amounts of oral bile acids (EARNEST DL, un-
published observations). The observation that cho-
lestyramine, a binder of bile acids, reduces hyperox-
aluria in some patients with this syndrome does not
prove that bile acids themselves affect oxalate ab-
sorption, because cholestyramine may itself bind ox-
alate 1138].
Treatment of hyperoxaluria
Treatment of the hyperoxaluric syndromes is de-
pendent on the specific pathogenetic mechanism in-
volved. In hyperoxaluria secondary to increased
ingestion of oxalate or a precursor, treatment in-
volves removal of the offending agent and appropri-
ate treatment for acute renal failure. Acute hemodial-
ysis may also be beneficial in reducing the serum
oxalate concentration, because oxalate is not pro-
tein-bound and is freely dialyzable. In the rare pa-
tient with pyridoxine deficiency, adequate replace-
ment of the vitamin should quickly reverse the
hyperoxaluria.
Treatment of the genetic forms of primary hyper-
oxaluria is more difficult. Attempts to reduce oxalate
production have generally been unsuccessful, includ-
ing dietary protein restriction to reduce glycine in-
take, trapping glycine as hippurate with benzoate,
and competitively inhibiting D-amino acid oxidase-
controlled oxidation of glycine to glyoxylate with
histidine and glutamate [151. Attempts to inhibit al-
dehyde dehydrogenase to reduce conversion of gly-
coaldehyde to glycolate and to inhibit xanthine oxi-
dase by administration of allopurinol [411 have not
been consistently effective. Compounds that inhibit
glycolic acid oxidase and lactic dehydrogenase are
effective in reducing oxalate synthesis in vitro [42],
but the potential toxicity of these compounds in vivo
has precluded their use in human subjects. Recently,
n-heptanoate and phenyllactate were shown to re-
duce oxalate synthesis in the perfused rat liver [43],
but these substances have not been studied in pa-
tients. No evident reduction in urinary oxalate excre-
tion could be demonstrated in two patients with
phenylketonuria and excessive excretion of phenyl-
lactate (WILLIAMS HE, SMITH LH JR, unpublished
observations). Reports of the effectiveness of tyro-
sine and succinimide in lowering urinary oxalate ex-
cretion require further study and confirmation in
patients with hyperoxaluria before these agents can
be recommended [44, 451.
Because pyridoxine deficiency can produce hyper-
oxaluria and because administration of pyridoxine
can reduce oxalate excretion in experimental animals
and normal subjects, presumably by increasing the
conversion of glyoxylate to glycine, this vitamin has
been administered to patients with primary hyperox-
aluria. In two studies [1, 46], administration of large
doses of pyridoxine (200 to 400 mg/day) to patients
with primary hyperoxaluria type I led to some reduc-
tion of oxalate excretion in some but not all of the
patients. For this reason, large doses of pyridoxine
should be administered to patients with this
syndrome.
A second approach to the treatment of hyperoxal-
uria has been directed toward reducing the tendency
to form calcium oxalate stones at any given level of
oxalate concentration. Maintenance of large urine
volumes is as important in these patients as it is in all
patients with recurrent nephrolithiasis. Calcium re-
striction is probably not indicated in these patients
because of the tendency for this maneuver to in-
crease urinary oxalate as a consequence of increased
oxalate absorption from the intestinal tract [47]. A
low oxalate diet may be of some help, although
absorbed oxalate is not a major source of urinary
oxalate in these patients.
Several studies have emphasized the inhibitory
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effect of magnesium and phosphate therapy (see
YENDT and COHANIM, this issue) on calcium oxalate
stone formation. Both magnesium oxide therapy and
a high phosphate intake have been reported to be of
therapeutic benefit in small numbers of patients with
primary hyperoxaluria, presumably by increasing
urinary inhibitory activity relative to calcium oxalate
crystal formation and growth [48, 49]. Other inhibi-
tors of calcium oxalate crystal growth such as the
diphosphonates have not yet been tested in patients
with primary hyperoxaluria.
Once chronic renal failure develops in the patient
with primary hyperoxaluria, therapy becomes even
more difficult [15]. Renal transplantation has gener-
ally not been successful in these patients in view of
the rapid reaccumulation of calcium oxalate deposits
in the transplanted kidney. Chronic hemodialysis has
now been attempted in several patients with primary
hyperoxaluria. Although good control of uremia has
been achieved, oxalosis has continued unabated and
ischemic infarcts of subcutaneous tissues have con-
tinued to appear despite adequate dialysis, probably
because dialysis does not remove sufficient oxalate
to keep up with the high production rates [15].
In contrast to the primary hyperoxaluric states,
treatment of enteric hyperoxaluria has been much
more satisfying. As noted previously, a low oxalate
diet, control of fat malabsorption with appropriate
use of low fat intake and medium-chain triglycerides,
and careful calcium supplementation have led to cor-
rection of the hyperoxaluria in most patients with
this syndrome [39]. It is theoretically possible, how-
ever, that in some patients with enteric hyperoxalu-
ria, calcium therapy may cause a sufficient increase
in urinary calcium to offset the reduction in urinary
oxalate. Cholestyramine, probably by its effect on
binding oxalate, may also decrease oxalate excretion
in these patients. In patients who have had an ileal
bypass procedure, restoration of normal gastrointes-
tinal continuity will reverse the hyperoxaluria.
Role of oxalate in idiopathic calcium oxalate
nephrolithiasis
In only a small percentage of patients with recur-
rent calcium oxalate stones has it been possible to
demonstrate that urinary oxalate excretion is signifi-
cantly elevated above the normal range. Despite this
observation, recent studies have suggested an impor-
tant role for oxalate in controlling stone formation in
patients with recurrent calcium oxalate stones. Sev-
eral studies by investigators in Leeds, England, have
raised important questions about the role of oxalate
in determining caLcium oxalate solubility in urine
[50—52]. Robertson, Peacock, and Nordin [50] dem-
onstrated that an increase in oxalate concentration
within the normal range of urinary oxalate leads to an
increase in the activity product (state of saturation)
of calcium oxalate in urine. This observation sug-
gests two important features about idiopathic cal-
cium oxalate stone disease: 1) decreasing the urinary
oxalate concentration within the normal range could
be important in controlling calcium oxalate crystal
formation in idiopathic stone formers, and 2) reduc-
ing urinary oxalate excretion even within the normal
range may be important in the treatment of patients
with idiopathic calcium oxalate nephrolithiasis.
Proof of these theories must await further studies
of frequent urinary oxalate values in large numbers
of patients with calcium oxalate stone disease and
clinical studies of compounds that might reduce uri-
nary oxalate excretion. Several clinics have reported
significantly increased oxalate excretion in patients
with idiopathic stone disease when compared with
normal subjects, even though the values do not ex-
ceed the "normal range" for urinary oxalate [2, 45,
53]. To date, no studies have been reported to ex-
plain the mechanism for this difference in oxalate
excretion. Nevertheless, this observation of a higher
oxalate excretion in stone-formers, together with the
work of Robertson et al [50], emphasizes the need to
study carefully variations of urinary oxalate in recur-
rent stone-formers.
Conclusion. Studies of the biosynthesis of oxalate
and its physicochemical properties have led to a
better understanding of recurrent calcium oxalate
nephrolithiasis. The mechanism for the hyperoxalu-
ria in the primary hyperoxaluria syndromes is now
better understood, and this has allowed development
of more rational treatment programs. Studies of the
enteric hyperoxaluria syndrome have demonstrated
the importance of increased oxalate absorption in the
pathophysiology of this condition. Attempts to con-
trol oxalate absorption by a variety of means have
generally been successful in reversing the hyperoxal-
uria. These studies have shed some light on the
problem of idiopathic calcium oxalate stone disease,
although the pathophysiologic mechanisms in this
disorder remain elusive.
Reprint requests to Dr. Hibbard F. Williams, Medical Service, 5
H 22, Sau Francisco General Hospital Medical Center, 1001
Portrero Avenue, San Francisco, California 94110, U.S.A.
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